You are looking at an old version of this article. Go to the latest version of the article.

Ed WildJeff CarrollBy Professor Ed Wild, Dr Leora Fox, Dr Rachel Harding, Dr Sarah Hernandez, and Dr Jeff Carroll Edited by Dr Jeff Carroll

Welcome to HDBuzz! This special page is for people who are new to Huntington’s disease, or new to the world of HD research.

Reading the articles linked here will help you pick up the basics of what Huntington’s disease is, and get up to speed with some of the most promising things scientists are doing to come up with effective treatments for HD.

Huntington’s disease - the bare essentials

  • Our Science FAQ covers the very basics of HD and introduces some ideas about why we need research to find treatments.

About HDBuzz

  • Our HDBuzz FAQ and People Page explain what HDBuzz is, and the people behind it.
  • And our Funding page explains where we get our money from and how we make sure HDBuzz is neutral and reliable.

The most promising possible treatments

Some of the world’s top scientists are working round the clock to develop treatments for Huntington’s disease - and real progress is being made. Dozens of possible treatments are being worked on, and every day a successful treatment gets one day closer. Here are our personal top four approaches.

  • Huntingtin lowering. Huntington’s disease is caused by a faulty protein, and huntingtin lowering drugs tell cells to make less of that protein. Huntingtin lowering is sometimes called “gene silencing”. Right now it is our best hope for an effective treatment. Read about it in our Gene Silencing Primer. In December 2017 the first successful huntingtin-lowering trial was announced. An “ASO” drug called HTTRx, made from artificial DNA, was injected into the spinal fluid of 46 volunteers 4 times each over 3 months. The drug successfully lowered the level of the mutant protein in the fluid, and was safe and well tolerated. A larger, longer trial called Generation-HD1 will test whether the drug, now renamed RG6042, can slow the progression of HD.
  • Several other approaches to Huntington-lowering are being developed and tested, including other ASO drugs, viruses containing instructions to make less of the huntingtin protein, and even “small molecules” that could be taken as a pill.

  • KMO inhibition. KMO is a chemical machine that determines the balance of certain helpful and harmful chemicals in cells. Our article on KMO Inhibitor Drugs explains how blocking it might be useful for treating Huntington’s disease.

  • Protein tagging. Scientists call it post-translational modification, we call it tagging. Our cells add little chemical tags to proteins, and the tags alter the proteins’ behavior. One approach to treating Huntington’s disease is altering the way cells tag the harmful protein. Read all about it in our article on Re-routing the Huntingtin Protein then you can read our latest articles on tagging.

Living with HD

Some of our most popular articles offer the latest information about day-to-day issues faced by Huntington’s disease family members.

  • ‘Making Babies’ explains how people at risk of HD can use assisted fertility methods to have HD-free kids - even if the would-be parents don’t want to be tested themselves.
  • Our article on the ‘Genetic Gray Area’ of HD sheds light on the often confusing topic of people whose HD genetic test result isn’t quite positive or negative, but somewhere in the middle.
  • Many HD-affected people are frustrated by a lack of interest or expertise from care professionals. Take a look at our article on Closing the Care Gap to find out about the expert guidance available to professionals - why not show it to the professionals looking after you?

Taking action

Successful treatments to prevent, slow, reverse or cure Huntington’s disease will arrive more quickly if more people help out. Here’s what we recommend:

  • Sign up for Enroll-HD, the largest global study of HD family members. Anyone from an HD family can sign up and you don’t need to have had a genetic test to do so. A short annual assessment involving questionnaires, thinking tests and a blood sample is all it takes to help us understand HD and put you in pole position for clinical trials.
  • In the USA, look at the HDSA’s TrialFinder, which will tell you what drug trials and other research studies are going on near you.
  • In Canada, look at the HSC’s Clinical Trial Locations page.
  • In Europe, check out the Euro-HD Network.
  • Elsewhere, the International Huntington Association will help you get involved.

Getting behind the headlines

A key mission of HDBuzz is to help our readers sort out the hope from the hype. News and blog stories can sometimes give a false impression of how promising a particular treatment is, or how soon it could deliver for HD-affected people.

  • Our Ten Golden Rules article suggests ten simple steps to help you draw hope from a science news story, without being disappointed by impossible promises.

Meanwhile, these articles deal with areas of HD research that generate a lot of headlines but - while interesting and potentially useful - aren’t necessarily able to live up to the hype.

The very latest

We regularly produce reports from major scientific meetings and conferences. They’re a great way to get an overview of all the hottest Huntington’s disease research. Catch up on the latest conference news here.

Make yourself at home!

HDBuzz is designed so that each article makes sense on its own and gives you all the background info you need. So don’t be afraid to explore.

  • Each article has a learn more box, containing links to original sources and background information.
  • Every article has a topics box so you can easily find content on a particular subject.

If there’s something about HD research you’d like explained but can’t find here, feel free to use the ‘Suggest an article’ box on the front page.

And to make sure you don’t miss anything exciting, follow us on Twitter or Facebook, or sign up for Email updates

Welcome aboard. We’re glad you found us.

The authors have no conflicts of interest to declare. For more information about our disclosure policy see our FAQ...